These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 18985033

  • 21. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
    Zhang GH, Yang WT, Zhou XY, Zeng Y, Lu HF, Shi DR.
    Zhonghua Yi Xue Za Zhi; 2007 Jan 16; 87(3):155-60. PubMed ID: 17425844
    [Abstract] [Full Text] [Related]

  • 22. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD, Markaki S, Karagianni E, Kyriakou V, Margariti A, Kyrkou E, Pavlakis K, Zaramboukas T, Skordalaki A, Bourli A, Markopoulos C, Pectasides D, Dimopoulos MA, Skarlos D, Fountzilas G.
    Breast Cancer Res Treat; 2006 Apr 04; 96(3):251-61. PubMed ID: 16538542
    [Abstract] [Full Text] [Related]

  • 24. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.
    Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM.
    J Pathol; 2003 Jul 04; 200(3):290-7. PubMed ID: 12845624
    [Abstract] [Full Text] [Related]

  • 25. Low expression of HER2 protein in breast cancer is biologically significant.
    Tovey SM, Reeves JR, Stanton P, Ozanne BW, Bartlett JM, Cooke TG.
    J Pathol; 2006 Nov 04; 210(3):358-62. PubMed ID: 16981252
    [Abstract] [Full Text] [Related]

  • 26. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.
    J Clin Oncol; 2007 Nov 20; 25(33):5194-202. PubMed ID: 17954712
    [Abstract] [Full Text] [Related]

  • 27. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M, Ahr A.
    Zentralbl Gynakol; 2006 Apr 20; 128(2):76-81. PubMed ID: 16673249
    [Abstract] [Full Text] [Related]

  • 28. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
    von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.
    J Clin Oncol; 2011 Jun 01; 29(16):2150-7. PubMed ID: 21519019
    [Abstract] [Full Text] [Related]

  • 29. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 30. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
    Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM.
    J Pathol; 2002 Jan 01; 196(1):17-25. PubMed ID: 11748637
    [Abstract] [Full Text] [Related]

  • 31. Quantitative determination of insulin-like growth factor 1 receptor mRNA in formalin-fixed paraffin-embedded tissues of invasive breast cancer.
    Fu P, Ibusuki M, Yamamoto Y, Yamamoto S, Fujiwara S, Murakami K, Zheng S, Iwase H.
    Breast Cancer; 2012 Oct 01; 19(4):321-8. PubMed ID: 21990036
    [Abstract] [Full Text] [Related]

  • 32. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R.
    Cancer J Sci Am; 1997 Oct 01; 3(1):21-30. PubMed ID: 9072304
    [Abstract] [Full Text] [Related]

  • 33. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
    Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K, Iwase H.
    Breast Cancer; 2013 Jul 01; 20(3):262-70. PubMed ID: 22362219
    [Abstract] [Full Text] [Related]

  • 34. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
    Fujiwara S, Ibusuki M, Yamamoto S, Yamamoto Y, Iwase H.
    Breast Cancer; 2014 Jul 01; 21(4):472-81. PubMed ID: 23100016
    [Abstract] [Full Text] [Related]

  • 35. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
    Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D.
    Clin Breast Cancer; 2007 Dec 01; 7(11):883-9. PubMed ID: 18269779
    [Abstract] [Full Text] [Related]

  • 36. The upgraded role of HER3 and HER4 receptors in breast cancer.
    Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.
    Crit Rev Oncol Hematol; 2010 May 01; 74(2):73-8. PubMed ID: 19481955
    [Abstract] [Full Text] [Related]

  • 37. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
    Biesaga B, Niemiec J, Ziobro M, Wysocka J, Kruczak A.
    Breast; 2011 Aug 01; 20(4):338-50. PubMed ID: 21507646
    [Abstract] [Full Text] [Related]

  • 38. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
    Pegolo E, Machin P, Riosa F, Bassini A, Deroma L, Di Loreto C.
    Cancer Cytopathol; 2012 Jun 25; 120(3):196-205. PubMed ID: 22298467
    [Abstract] [Full Text] [Related]

  • 39. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G.
    Breast Cancer Res Treat; 2012 Apr 25; 132(2):609-19. PubMed ID: 22187126
    [Abstract] [Full Text] [Related]

  • 40. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y.
    Jpn J Clin Oncol; 2009 Aug 25; 39(8):484-90. PubMed ID: 19477897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.